67973-32-4 Usage
Uses
Used in Pharmaceutical Industry:
3,5-DIBROMO-4-METHYLBENZOIC ACID is used as an intermediate in the synthesis of pharmaceuticals for its potential antimicrobial and antifungal properties. It plays a crucial role in the development of new drugs targeting various infections and diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 3,5-DIBROMO-4-METHYLBENZOIC ACID is utilized as an intermediate in the production of agrochemicals. Its properties contribute to the development of effective pesticides, herbicides, and other agricultural chemicals that protect crops and enhance agricultural productivity.
Used in Dye Industry:
3,5-DIBROMO-4-METHYLBENZOIC ACID is employed as a building block in the synthesis of dyes, contributing to the creation of a wide range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Advanced Materials and Specialty Chemicals Production:
3,5-DIBROMO-4-METHYLBENZOIC ACID is also used as a key component in the production of advanced materials and specialty chemicals. Its unique structure and properties make it suitable for developing high-performance materials for various applications, such as coatings, adhesives, and composites.
Check Digit Verification of cas no
The CAS Registry Mumber 67973-32-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,9,7 and 3 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 67973-32:
(7*6)+(6*7)+(5*9)+(4*7)+(3*3)+(2*3)+(1*2)=174
174 % 10 = 4
So 67973-32-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H6Br2O2/c1-4-6(9)2-5(8(11)12)3-7(4)10/h2-3H,1H3,(H,11,12)
67973-32-4Relevant academic research and scientific papers
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors
Rice, Kenneth D.,Kim, Moon H.,Bussenius, Joerg,Anand, Neel K.,Blazey, Charles M.,Bowles, Owen J.,Canne-Bannen, Lynne,Chan, Diva S.-M.,Chen, Baili,Co, Erick W.,Costanzo, Simona,Defina, Steven C.,Dubenko, Larisa,Engst, Stefan,Franzini, Maurizio,Huang, Ping,Jammalamadaka, Vasu,Khoury, Richard G.,Klein, Rhett R.,Laird, A.Douglas,Le, Donna T.,Mac, Morrison B.,Matthews, David J.,Markby, David,Miller, Nicole,Nuss, John M.,Parks, Jason J.,Tsang, Tsze H.,Tsuhako, Amy L.,Wang, Yong,Xu, Wei
supporting information; scheme or table, p. 2693 - 2697 (2012/05/20)
Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development.
